Bacteria detect phages via viral protease that cleaves host sensor
A newly identified bacterial immune trigger could improve phage therapy and reveal immune origins shared with humans.
Medicine & Biotech
Clinical AI, drug discovery, devices, and regulatory approvals.
Gastroesophageal Adenocarcinoma Care Advances, but Biomarker Gaps Persist
Perioperative immunotherapy and targeted agents have reshaped gastroesophageal adenocarcinoma treatment, yet validated biomarkers for precision guidance remain incomplete.
NIH Bets on mRNA Cancer Vaccines; FDA Approves Tucatinib Combo
A broad cancer update covers an NIH push for therapeutic mRNA vaccines, an FDA approval in HER2-positive breast cancer, and new findings on genetic screening and CAR-T resistance.
Longevity Supplement Nicotinamide Riboside Fails in Parkinson's Trial
A phase III trial found that the over-the-counter supplement nicotinamide riboside did not slow early Parkinson's disease and was linked to modestly worse symptoms than placebo.
eHealth expands voice AI after Medicare enrollment call surge
A health insurance agency's shift from pilot to full-time voice AI shows how insurers are using automation to manage enrollment-period call surges.
Fathers' early deaths after childbirth often preventable, Georgia study finds
A study of more than 130,000 births found hundreds of fathers died within five years, with most deaths from preventable causes.
Dermatomyositis Care Shifts as New Drugs and Trials Emerge
Recent FDA approval of brepocitinib and promising trial data signal a changing treatment landscape for dermatomyositis, though traditional therapies remain first-line.
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised
A new oral helicase-primase inhibitor offers a treatment option for immunocompromised patients with herpes lesions that no longer respond to standard antivirals.
Quay no longer leading candidate for NIAID director, source says
A biotech executive who promoted the lab-leak theory for Covid-19 is expected to take a consulting role instead of heading the top U.S. infectious disease institute.
FDA Approves New Long-Acting Olanzapine Injection Without PDSS Monitoring
A once-monthly subcutaneous olanzapine formulation offers a new option for schizophrenia patients, avoiding the post-injection monitoring required by earlier long-acting versions.
Undeclared Steroids Found in a Third of Tested OTC Skin Creams
A targeted analysis of online-marketed skin products found prescription-only ingredients, including a superpotent steroid, in one-third of samples.
Roche partners with Chinese startup on molecular glue medicines
The discovery-focused deal, potentially worth nearly $1 billion, signals Big Pharma's growing interest in Chinese biotech innovation.
NIH Funding Uncertainty Stymies U.S. Researchers
A STAT podcast examines how unpredictable NIH spending is disrupting biomedical research and feeding biotech investor gloom.
Dr. Mike for 'The Bachelor,' AAP Antics, and Plague Context
A roundup of healthcare social media moments, from a reality TV rumor to pediatricians' conference antics and plague context.
Argenx's Vyvgart fails Sjögren's trial, stock drops
A Phase 3 failure for Vyvgart in Sjögren's disease offsets progress on a celiac candidate and pressures Argenx's valuation.
Accelerated Biological Aging Tied to Higher Early-Onset Colon Cancer Risk
A large Korean cohort study links accelerated biological aging to a substantially increased risk of early-onset colorectal and colon adenocarcinoma.
Viatris to acquire Pacira for $1.65B, adding non-opioid pain drugs
The deal gives Viatris two non-opioid pain treatments with nearly $700 million in combined 2025 sales, though generic competition looms.
Royal Family Doctor Murdered; Spine Settlement, Telehealth Fraud Conviction
A weekly legal roundup shows healthcare providers facing criminal charges and large settlements for fraud and misconduct.